Niclosamide

Product Description

Niclosamide is an inhibitor of the STAT3 signaling pathway; inhibits the activation, nuclear translocation and transactivation of STAT3. Niclosamide displays selectivity for STAT3 over STAT1, STAT5, JAK1, JAK2 and Src kinases. It inhibits the transcription of STAT3 target genes and induces cell growth inhibition, apoptosis and cell cycle arrest of cancer cells with constitutively active STAT3. It also reversibly inhibits mTORC1 signaling and stimulates autophagy in vitro; displays antineoplastic effects in acute myelogenous leukemia (AML) stem cells. In addition, niclosamide inhibits SARS-CoV-2 replication in vitro (IC₅₀ = 0.34 μM in Vero E6 plaque assay) through suppression of TMEM16F activity.

Solubility

Preparing Stock Solutions for Niclosamide

The following data is based on the product molecular weight 325.99

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.25 mM	12.27 mL	61.35 mL	122.70 mL
1.25 mM	2.45 mL	12.27 mL	24.54 mL
2.5 mM	1.23 mL	6.14 mL	12.27 mL
12.5 mM	0.25 mL	1.23 mL	2.45 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Braga Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature 2021 PMID: 33827113
• Jin Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-κB pathway and generation of reactive oxygen species. Cancer Res. 2010 PMID: 20215516
• Ren Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med.Chem.Lett. 2010 PMID: 24900231
• Balgi Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 2009 PMID: 19771169